7 Ways to Build Clinical Evidence Without a Full RCT

You do not need a randomized controlled trial to make most early-stage clinical claims credible. Seven cheaper designs — single-arm pilots, pre-post studies, retrospective chart reviews, case series, pragmatic trials, real-world evidence, and quasi-experimental comparisons — each support a specific, narrower claim than an RCT does. Match the design to the claim you actually need to prove, not the one a reviewer might ask for someday.

Quick Answer: Start with the cheapest design that supports your next buyer conversation — usually a single-arm pilot or a pre-post study. Save the RCT for when a regulator, a payer, or a claim of causal superiority actually requires it. Most seed and Series A milestones don't.

An RCT is the right instrument for a specific job: isolating cause from every plausible alternative explanation by randomly assigning who gets the intervention and who doesn't. That rigor is exactly why it is slow and expensive — recruitment, randomization infrastructure, a control arm you have to run in parallel, and often a year or more before you have a result. For a founder trying to unlock a pilot contract, a seed round, or a first payer conversation, that timeline is frequently the wrong trade. This guide walks through seven evidence designs that cost less and move faster, what each one can honestly claim, and where each one breaks down — so you can pick the cheapest design that still gets you through your next door, a decision covered from the buyer side in our guide to clinical evidence for digital health startups.

Selection criteria: rigor, cost, speed, and claim strength

The right study design is the cheapest one that supports the specific claim your next buyer needs to hear — nothing more. Four variables trade against each other in every design decision, and treating them as independent is how founders end up either under-evidenced for their ask or over-building a trial nobody asked for.

• Rigor — how well the design rules out explanations for your result other than "the product worked." A randomized, controlled design rules out the most; an uncontrolled case series rules out the least.
• Cost — direct spend (staff time, data infrastructure, statistical support, participant incentives) plus the opportunity cost of the runway it consumes.
• Speed — how long from protocol to a result you can put in a deck or a claim. This compounds with cost: a slow design is also an expensive one, because burn keeps running while you wait.
• Claim strength — what you are actually allowed to say afterward. A study that shows your metric improved is not the same as a study that shows your product caused the improvement, and buyers who understand the difference will ask which one you ran.

The mistake to avoid runs in both directions. Running an underpowered pilot and then describing its output as proof of clinical efficacy invites exactly the kind of scrutiny that erodes trust with a sophisticated payer or clinical partner. The opposite mistake — commissioning trial-grade rigor for a claim a testimonial would have satisfied — burns months of runway a startup didn't have to spend. The table in this article exists to help you place your specific claim against the cheapest design that still earns it.

Single-arm pilot studies: fastest way to show your product does something

Verdict: run this first, almost always — it is the cheapest way to generate a real, if narrow, result. A single-arm pilot enrolls one group, applies your intervention, and measures the outcome. There is no comparison group and no randomization; everyone in the study gets the product.

This design answers a narrow but genuinely useful question: does anything measurable happen when real users use your product in a real setting? It is the natural first evidence step after usability testing and before you invest in anything with a control arm, and it pairs directly with the earlier-stage work covered in designing a digital health pilot study.

What it cannot prove: causation. If your metric improved during the pilot, a single-arm design cannot tell you whether your product caused that improvement, whether participants would have improved anyway (regression to the mean, natural disease course, seasonal effects), or whether simply being watched changed behavior — a well-documented phenomenon sometimes called the Hawthorne effect. Present single-arm results as "this is what we observed," not "this is what we caused," and expect a sophisticated buyer to ask the difference.

Pre-post studies: measuring change within the same participants

Verdict: a modest upgrade over a single-arm pilot, at almost no extra cost, because you already have a baseline. A pre-post design measures the same outcome in the same participants before the intervention starts and again after, so the study reports a change rather than only an endpoint.

The advantage over a pure single-arm pilot is that each participant serves as their own baseline, which controls for stable differences between people (age, severity, prior history) that a between-group comparison would need a control arm to handle. It is inexpensive to run because you are already collecting the "before" number as part of enrollment.

What it cannot prove: that anything besides the passage of time explains the change. Pre-post studies are especially vulnerable to regression to the mean — people often enroll in a study or start using a product at a low point, and a return toward their typical baseline can look identical to a treatment effect. They are also vulnerable to any external event that occurred between the two measurements. Report the before/after difference plainly; do not extrapolate it into a causal claim without a comparison group.

Retrospective chart review: evidence from data you already have

Verdict: choose this when you have an existing dataset and want a fast, low-cost look backward. A retrospective chart review examines records already collected for other purposes — clinical charts, usage logs, claims data — to answer a question you did not design the original data collection to answer.

The appeal is almost entirely economic: no new enrollment, no new data collection infrastructure, and a result that can sometimes be produced in weeks rather than months if you already have partner or pilot-customer data to mine. It is a strong fit for showing patterns in an existing user base — for instance, whether engagement correlates with an outcome you're tracking anyway.

What it cannot prove: anything a dataset collected for a different purpose wasn't built to measure cleanly. Retrospective data is prone to missing fields, inconsistent documentation, and selection bias — the people in your existing dataset are not necessarily representative of the population you'll eventually sell to. Because you are choosing what to look for after the data already exists, retrospective findings are best treated as hypothesis-generating: a signal worth testing prospectively, not a conclusion to build a claim on by itself.

Case series: documented reports across your earliest users

Verdict: useful mainly as qualitative, descriptive evidence early on — not a substitute for anything quantitative. A case series is a structured, detailed description of outcomes across a small number of individual users or patients, often the very first handful who used the product.

Case series are cheap, fast, and good at surfacing the texture of how a product actually gets used — the workflow friction, the unexpected use case, the outcome nobody had a metric for yet. They are a natural companion to early customer-discovery interviews and can be a useful narrative addition to a deck, especially paired with the qualitative validation work described in the complete guide to startup idea validation.

What it cannot prove: anything generalizable. A handful of individual accounts, however compelling, cannot establish a rate, an effect size, or even reliably represent your typical user — the cases you have written up are, almost by definition, the ones that happened to be interesting or accessible enough to document. Use a case series to illustrate a mechanism or a use case, never to claim a typical or expected outcome.

Pragmatic trials: testing your product under real-world conditions

Verdict: reach for this once you need a comparison group but can't afford — or don't yet need — the full infrastructure of an explanatory RCT. A pragmatic trial still compares an intervention group against a control, and often still randomizes, but it does so under the loose, real-world conditions your product will actually be used in rather than the tightly controlled protocol of a classical explanatory RCT: broader eligibility criteria, real clinical or consumer settings, and outcomes that matter to a day-to-day user rather than a narrow physiological endpoint.

This makes pragmatic trials meaningfully cheaper and faster to run than an explanatory RCT while still producing a genuine comparison. It also produces a result that generalizes better to your actual customer base, since the trial conditions look like the deployment conditions.

What it cannot prove: the same tightly isolated causal mechanism an explanatory RCT can. Because eligibility is broader and conditions are less controlled, a pragmatic trial has more noise in it — real-world variation you didn't standardize away. It answers "does this work under real conditions?" rather than "does this work when every other variable is held constant?" — a genuinely different, and for most commercial purposes more useful, question, but not an interchangeable one.

Real-world evidence: evidence generated after launch

Verdict: the design that scales with your user base instead of your study budget — but it takes volume and time to accumulate. Real-world evidence (RWE) is evidence drawn from data generated during actual product use after commercial launch — usage patterns, outcomes reported through the product, claims data, registries — rather than from a purpose-built study.

The advantage compounds over time: every user who adopts your product after launch is a potential data point, at close to zero marginal cost per participant compared to running a dedicated study. Regulators and payers increasingly treat well-constructed real-world evidence as a legitimate complement to trial evidence, particularly for tracking long-term safety and effectiveness once a product is already in use — though the bar for what counts as "well-constructed" is doing a lot of work in that sentence.

What it cannot prove: anything reliable before you have real launch volume, and it cannot on its own untangle causation from the same confounding that limits observational data generally — the users who adopt and stick with a product are rarely a random sample of everyone who could have. RWE is a post-launch asset you build deliberately (by instrumenting the right outcomes from day one), not something you can retroactively manufacture once someone asks for it.

Quasi-experimental designs: comparison without randomization

Verdict: the strongest non-randomized option when you have a natural comparison group but can't ethically or practically randomize. A quasi-experimental design compares an intervention group against a control group — but assigns people to those groups by something other than random chance: geography, timing of rollout, an existing waitlist, or a matched comparison group selected after the fact to resemble your treated group on key characteristics.

This gets you most of the benefit of having a comparison group — a baseline to measure your effect against, rather than just a before/after within one group — without the cost, timeline, and infrastructure of running a full randomization protocol. It is a natural fit when you are rolling a product out in phases anyway, since an early-access cohort and a not-yet-onboarded cohort can sometimes serve as a rough comparison.

What it cannot prove: freedom from selection bias. Whatever process assigned people to groups instead of chance — waitlist position, geography, a clinician's own judgment about who to refer — can also be correlated with the outcome you're measuring, and no amount of statistical adjustment afterward fully closes that gap. Quasi-experimental results are stronger than a single-arm or pre-post study, but they remain a step below a genuinely randomized comparison, and should be labeled as such.

Comparing the seven designs on cost, speed, and evidence strength

The table below lines up all seven designs against the criteria from the selection framework above, so you can place your own claim against the cheapest design that still supports it.

Read the table as a ladder, not a menu: most startups climb it in roughly this order as claims get bigger and buyers get more sophisticated, rather than picking a design once and staying there. The single-arm pilot and case series sit at the bottom because they're the fastest way to get any real signal; the RCT sits at the top, included here only as the reference point everything else is being compared against, since it is not one of the seven alternative designs this guide covers.

Key Takeaways

• Match the design to the claim, not to what sounds rigorous. A single-arm pilot is the right tool for "users engaged with the product"; it is the wrong tool for "the product caused this outcome."
• Single-arm pilots and case series are the cheapest way to get a first real signal, but neither can separate your product's effect from time, chance, or the act of being observed.
• Pre-post studies add a baseline almost for free but stay vulnerable to regression to the mean and any external event between the two measurements.
• Retrospective chart review and real-world evidence both reuse data you already have or are already generating, trading cost for the limits of data collected for a different original purpose.
• Pragmatic trials and quasi-experimental designs are the two cheaper paths to an actual comparison group, closing most — not all — of the gap to a randomized result.
• Save the full RCT for when a regulator, a payer, or a causal superiority claim genuinely requires it. Most early commercial milestones don't, and the runway an RCT consumes is usually better spent proving product-market fit first — the discipline Eric Ries lays out in The Lean Startup for testing the riskiest assumption with the smallest sufficient experiment applies as directly to clinical claims as it does to any other product hypothesis.

Frequently Asked Questions

Do I need an RCT before I can sell to hospitals or health systems?

Usually not at first contact. Most health systems will pilot a product on pragmatic evidence — a single-arm pilot, a pre-post study, or a small pragmatic trial — before committing to anything larger. An RCT typically becomes necessary later, for a specific efficacy claim, a regulatory submission, or a payer contract tied to outcomes.

Can I combine several of these designs instead of running just one?

Yes, and it's common practice. A typical sequence runs a single-arm pilot first, adds a pre-post comparison once you have a stable protocol, and layers in real-world evidence continuously after launch — each design filling a gap the previous one left, rather than one design trying to do everything.

How much does a pragmatic trial cost compared to a full RCT?

There's no fixed number — it depends heavily on sample size, duration, and data infrastructure — but pragmatic trials are generally cheaper and faster than explanatory RCTs because they use broader eligibility criteria, real-world settings, and simpler outcome measures instead of the tightly controlled protocol an RCT requires.

Is real-world evidence legally acceptable for regulatory or payer submissions?

It can be, depending on the regulator, the claim, and how the evidence was collected. Well-constructed real-world evidence is increasingly accepted as a complement to trial data, especially for tracking safety and long-term effectiveness — but acceptance standards vary by jurisdiction and claim type, so confirm the specific bar with the regulator or payer you're targeting before you build your data collection around it.